139 related articles for article (PubMed ID: 22147075)
21. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
[TBL] [Abstract][Full Text] [Related]
22. Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH.
Ozdemir M; Crewe KH; Tucker GT; Rostami-Hodjegan A
J Clin Pharmacol; 2004 Dec; 44(12):1398-404. PubMed ID: 15545311
[TBL] [Abstract][Full Text] [Related]
23. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract][Full Text] [Related]
24. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers.
Schoedel KA; Pope LE; Sellers EM
Clin Drug Investig; 2012 Mar; 32(3):157-69. PubMed ID: 22283559
[TBL] [Abstract][Full Text] [Related]
25. Effects of steady-state lasofoxifene on CYP2D6- and CYP2E1-mediated metabolism.
Moller RA; Fisher JM; Taylor AE; Kolluri S; Gardner MJ; Obach RS; Walsky RL
Ann Pharmacother; 2006 Jan; 40(1):32-7. PubMed ID: 16368922
[TBL] [Abstract][Full Text] [Related]
26. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
[TBL] [Abstract][Full Text] [Related]
27. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
[TBL] [Abstract][Full Text] [Related]
28. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic comparison of a new glimepiride 1-mg + metformin 500-mg combination tablet formulation and a glimepiride 2-mg + metformin 500-mg combination tablet formulation: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy, fasting Korean male volunteers.
Kim BH; Shin KH; Kim J; Lim KS; Kim KP; Kim JR; Cho JY; Shin SG; Jang IJ; Yu KS
Clin Ther; 2009 Nov; 31(11):2755-64. PubMed ID: 20110017
[TBL] [Abstract][Full Text] [Related]
30. Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance.
Borges S; Li L; Hamman MA; Jones DR; Hall SD; Gorski JC
Drug Metab Dispos; 2005 Jul; 33(7):1052-5. PubMed ID: 15821042
[TBL] [Abstract][Full Text] [Related]
31. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
32. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
33. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus.
Boni J; Abbas R; Leister C; Burns J; Jordan R; Hoffmann M; DeMaio W; Hug B
Cancer Chemother Pharmacol; 2009 Jul; 64(2):263-70. PubMed ID: 19015855
[TBL] [Abstract][Full Text] [Related]
34. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
[TBL] [Abstract][Full Text] [Related]
35. No effect of the new antidepressant reboxetine on CYP2D6 activity in healthy volunteers.
Avenoso A; Facciolà G; Scordo MG; Spina E
Ther Drug Monit; 1999 Oct; 21(5):577-9. PubMed ID: 10519458
[TBL] [Abstract][Full Text] [Related]
36. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Ruiz-Garcia A; Masters JC; Mendes da Costa L; LaBadie RR; Liang Y; Ni G; Ellery CA; Boutros T; Goldberg Z; Bello CL
J Clin Pharmacol; 2016 Feb; 56(2):223-30. PubMed ID: 26179237
[TBL] [Abstract][Full Text] [Related]
37. Investigation of terbinafine as a CYP2D6 inhibitor in vivo.
Abdel-Rahman SM; Gotschall RR; Kauffman RE; Leeder JS; Kearns GL
Clin Pharmacol Ther; 1999 May; 65(5):465-72. PubMed ID: 10340911
[TBL] [Abstract][Full Text] [Related]
38. Application of a physiologically based pharmacokinetic model for the evaluation of single-point plasma phenotyping method of CYP2D6.
Chen R; Rostami-Hodjegan A; Wang H; Berk D; Shi J; Hu P
Eur J Pharm Sci; 2016 Sep; 92():131-6. PubMed ID: 27412587
[TBL] [Abstract][Full Text] [Related]
39. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Piscitelli J; Chen J; LaBadie RR; Salageanu J; Chung CH; Tan W
Clin Drug Investig; 2022 Mar; 42(3):221-235. PubMed ID: 35195881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
